The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT-EHA CAR-T 2019 | The future landscape of CAR T-cell therapy
In this video, Elaine Vickers, PhD, of Science Communicated Ltd., Manchester, UK, discusses the future of immunotherapy with CAR T-cells. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Dr Vickers mentions the most anticipated upcoming strategies that may improve the performance of CAR T-cell therapy in treating cancer. This meeting was co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
